[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-cell-carcinoma-kidney-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-cell-carcinoma-kidney-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,46,77,120,180,221,249,281,307,346,367,397,426,460,480,501],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100617636","radical-nephrectomy-with-vs-without-template-lymph-node-dissection-in-high-risk-renal-cell-carcinoma-t-lnd-rcc-100617636",false,"NCT07321197","Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC)","Template Lymph Node Dissection for Tumor Control in High-Risk Renal Cell Carcinoma: A Prospective, Open-Label, Multicenter, Randomized Controlled Trial","RECLND","Inclusion Criteria:\n\n* Signed informed consent form.\n* Age \\> 18 years.\n* Candidate for radical nephrectomy with or without lymph node dissection.\n* High-risk renal cell carcinoma defined as: At least ONE of: Clinical stage cT3-4 N0-1 M0 (AJCC 8th ed); OR radiologically visible lymph node \\>1cm; OR M1 disease rendered no evidence of disease (NED) after local therapy; OR radiologically determined rT4 stage. OR at least TWO of: Renal vein or inferior vena cava tumor thrombus; OR nuclear grade 3-4 or sarcomatoid differentiation or coagulative necrosis; OR tumor size \\>= 10cm; OR hematuria and\u002For local symptoms.\n* Measurable disease as per RECIST v1.1.\n* ECOG performance status of 0 or 1.\n* Adequate bone marrow, renal, and hepatic function.\n* For women and men of childbearing potential, agreement to use effective contraception during the study period.\n\nExclusion Criteria:\n\n* Prior radiotherapy, chemotherapy, major surgery, or targeted therapy for RCC.\n* Concurrent other active malignancy (except controlled malignancies not affecting 2-year survival).\n* Candidate for partial nephrectomy or ablation per multidisciplinary team assessment.\n* Preoperative imaging indicates unresectable regional lymph nodes.\n* renal tumors or known hereditary RCC syndrome.\n* Diagnosis of any other active malignancy within the past 5 years.\n* Active autoimmune disease or history of autoimmune disease.\n* Use of immunosuppressive agents within 2 weeks prior to enrollment.\n* Poorly controlled cardiac or clinical symptoms.\n* Coagulopathy or bleeding tendency.\n* Active gastrointestinal conditions with risk of bleeding or perforation.\n* History of significant bleeding or thromboembolic events within specified timeframes.\n* Active infection or unexplained fever \\>38.5°C.\n* Abdominal fistula, gastrointestinal perforation, or abscess within 4 weeks prior.\n* History of pulmonary fibrosis, interstitial lung disease, or severely impaired pulmonary function.\n* Known immunodeficiency or active hepatitis.\n* Participation in another clinical trial within 1 month.\n* Known history of drug abuse or alcohol addiction.\n* Inability or unwillingness to bear the self-paid portion of examination and treatment costs.\n* Any condition that, in the investigator's judgment, may compromise patient safety or study conduct.","ALL","18 Years",{"count":20,"type":21},220,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a more thorough lymph node removal surgery, called \"Template Lymph Node Dissection,\" can help prevent cancer from returning and help patients live longer, compared to removing only a few enlarged lymph nodes, in patients with high-risk kidney cancer. The main questions it aims to answer are:\n\nDo patients who receive template lymph node dissection live longer without their cancer returning (Disease-Free Survival)? Do patients who receive template lymph node dissection live longer overall (Overall Survival)? Is the more extensive lymph node surgery as safe as the limited surgery? Researchers will compare the Template Lymph Node Dissection group to the Limited Node Resection group to see the effects on cancer control and safety.\n\nParticipants will:\n\nBe randomly assigned to one of the two surgical groups. Undergo surgery to remove their kidney and the assigned lymph nodes. Attend regular follow-up visits with imaging scans (like CT or MRI) for the first 5 years after surgery to monitor if the cancer returns.\n\nBe followed for their overall survival status for up to 10 years.",[27],"Renal Cell Carcinoma (Kidney Cancer)",[29,30,31,32],"Template Lymph Node Dissection","High-Risk Neoplasm","Randomized Controlled Trial","Surgical Oncology","RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-25","ACTUAL",{"date":39,"type":37},"2025-09-01",{"date":41,"type":21},"2033-09-30",{"name":43,"class":44},"Tianjin Medical University Second Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":5},"100595105","phase-4-digital-monitoring-of-self-reported-symptoms-by-patients-treated-with-cabozantinib-plus-nivolumab-for-advanced-clear-cell-renal-carcinoma-100595105","NCT07028125","Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma","Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma: The CANIQOL Multicentre Study","CANIQOL","Inclusion Criteria:\n\n* Patient older than 18 years\n* Diagnosis of advanced\u002Fmetastatic Renal Cell Carcinoma (RCC) with a clear-cell component\n* No prior systemic treatment for RCC\n* Physician-initiated decision prior to study enrollment to treat with cabozantinib and nivolumab in combination, in first line for advanced\u002Fmetastatic RCC, according to approved local labels\n* Female subjects of childbearing potential must not be pregnant at screening and during treatment by Cabozantinib and Nivolumab. Effective methods of contraception must be used throughout the course of treatment and for at least 5 months after the end of treatment. Sexually active fertile subjects and their partners must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the study and 5 months after the last dose of study treatment, even if oral contraceptives are also used.\n* Subject affiliated to an appropriate social security system\n* Patient has signed informed consents obtained before any trial related activities and according to local guidelines\n\nExclusion Criteria:\n\n* Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol\n* Current participation in another clinical study and\u002For in an investigational program with any intervention that could possibly interfere with the treatment and impact this study\n* Patient with history of allergy or hypersensitivity to components of the study drugs\n* Patient with contraindication to the study drugs\n* Pregnant or lactating woman\n* Patient unable to use digital tools\n* Patient deprived of liberty or placed under the authority of a tutor\n* Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol",{"count":55,"type":21},83,[57],"PHASE4","The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal cell carcinoma (RCC) in real life during the first 3 months of combined treatment",[27,60,61],"Metastatic Renal Cell Carcinoma","Locally Advanced",[63,64,65,66,67],"kidney cancer","metastatic","cabozantinib","nivolumab","digital monitoring system","2026-06-04",{"date":70,"type":37},"2026-06-05",{"date":72,"type":37},"2025-10-01",{"date":74,"type":21},"2029-01",{"name":76,"class":44},"Centre Francois Baclesse",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":97,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":119},"100518120","phase-1-ko-2806-monotherapy-and-combination-therapies-in-advanced-solid-tumors-100518120","NCT06026410","KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors","FIT-001","Inclusion Criteria:\n\n* At least 18 years of age.\n* Histologically or cytologically confirmed advanced solid tumors\n\n  * Arm #1 (KO-2806 monotherapy): Patients who have progressed on, or are refractory to, standard of care (SOC) treatments with advanced solid tumors, specifically: HRAS-mutant and\u002For amplified tumors (any solid tumor type); HRAS overexpression (only for HNSCC tumors); KRAS and\u002For NRAS, and\u002For HRAS-mutant and\u002For amplified NSCLC or CRC; KRAS-mutant and\u002For amplified PDAC\n  * Arm #2 (Combination): Patients who have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC with predominantly clear cell subtype; non-clear cell RCC patients who are either treatment-naïve or have received any prior systemic treatment for locally advanced and metastatic RCC.\n  * Arm #3 (Combination): Patients who have received at least 1 prior systemic therapy including available approved SOC treatments for KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC.\n  * Arm #4 (Combination): Patients must be cabozantinib-naïve and have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic ccRCC, but no more than 3 prior systemic anticancer therapies.\n  * Arm #5 (Cabozantinib monotherapy): Patients must be cabozantinib-naïve and have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic ccRCC, but no more than 3 prior systemic anticancer therapies.\n  * Arm #6 (Cabozantinib rollover to combination): Patients must be cabozantinib-naïve and have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic ccRCC, but no more than 3 prior systemic anticancer therapies.\n  * Arm #7 (Combination): Patients who have received at least 1 prior systemic therapy including available approved SOC treatments for KRAS G12C-mutant locally advanced or metastatic NSCLC\n* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Karnofsky Performance Status of 70 or higher with no clinically significant deterioration over the previous 2 weeks.\n* Acceptable liver, renal, endocrine, and hematologic function.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Any use of anticancer therapy within 14 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1.\n* Prior treatment with an FTI or HRAS inhibitor.\n* Major surgery, other than local procedures, within 28 days prior to Cycle 1 Day 1, without complete recovery.\n* Spinal cord compression, leptomeningeal disease, or clinically active CNS metastases.\n* Toxicity (excluding alopecia) from prior therapy that has not been completely resolved to baseline at the time of consent.\n* Active or prior documented autoimmune or inflammatory disorders within the past 5 years prior to Cycle 1 Day 1 (with exceptions).\n* Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.\n* Inability to swallow, impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the trial drugs.\n* Inadequate cardiac and\u002For vascular function, including receipt of treatment for unstable angina, myocardial infarction, and\u002For cerebrovascular attack within the prior 6 months, mean QTcF ≥470 ms, or Class II or greater congestive heart failure.\n* Other invasive malignancy within 2 years.\n* Other protocol-defined exclusion criteria may apply.",{"count":86,"type":21},300,[88],"PHASE1","This first-in-human (FIH) dose-escalation and dose-validation\u002Fexpansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.",[91,92,93,94,95,27,96],"Solid Tumors With HRAS Alterations","Non Small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Clear Cell Renal Cell Carcinoma (ccRCC)","Non Clear Cell Renal Cell Carcinoma (nccRCC)",[98,99,100,101,102,103,104,105,106,107,108,109],"HRAS","KRAS","NRAS","Farnesyltransferase inhibitor (FTI)","Tyrosine Kinase inhibitor (TKI)","Phase 1","KRAS G12C inhibitor","NSCLC","ccRCC","RCC","PDAC","CRC",{"date":111,"type":37},"2026-06-08",{"date":113,"type":37},"2023-10-18",{"date":115,"type":21},"2027-04",{"name":117,"class":118},"Kura Oncology, Inc.","INDUSTRY",38,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":130,"studyType":131,"phases":4,"briefSummary":132,"conditions":133,"keywords":146,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100642988","registry-of-minimally-invasive-cancer-treatment-using-spectral-angio-ct-image-guidance-100642988","NCT07636148","Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance","Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice","PreciseOnco","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;\n* Use of spectral angio-CT image guidance as part of standard care;\n* Written confirmed consent.\n\nExclusion Criteria:\n\n* Patients who are declared incapacitated;\n* Patients suffering from psychic disorders that make a comprehensive judgement impossible.",{"count":129,"type":21},2000,"3 Years","OBSERVATIONAL","This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.\n\nDuring these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.\n\nNo experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.",[134,135,136,137,138,139,140,27,141,142,143,144,145],"Liver Cancer (Primary and Metastatic)","Lung Cancer (Diagnosis)","Bone Cancer Metastatic","Bone Cancer Tumor","Kidney Tumors","Renal Cancer","Hepatocellular Carcinoma (HCC)","Renal Cell Carcinoma (RCC)","Musculoskeletal Cancers","Musculoskeletal Tumors","Bone Tumors","Lung Tumors",[147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168],"Spectral CT","Dual-layer detector CT","Angio-CT","Image-guided therapy","Interventional oncology","Thermal ablation","Radiofrequency ablation","Microwave ablation","Cryoablation","Transarterial chemoembolization","Transarterial radioembolization","Transarterial embolization","Local tumor control","Tumor recurrence","Progression-free survival","Hepatocellular carcinoma","Liver metastases","Renal cell carcinoma","Lung tumors","Musculoskeletal tumors","Registry","Multicenter","NOT_YET_RECRUITING","2026-06-03",{"date":172,"type":37},"2026-06-09",{"date":174,"type":21},"2026-07-01",{"date":176,"type":21},"2030-12-31",{"name":178,"class":44},"Mark C Burgmans, MD PhD",3,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":190,"conditions":191,"keywords":206,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":5},"100437810","solid-tumor-analysis-for-hla-loss-of-heterozygosity-loh-and-apheresis-for-car-t--cell-manufacturing-100437810","NCT04981119","Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing","An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing","BASECAMP-1","Key Eligibility Criteria (additional criteria may apply) Part 1 Key Inclusion Criteria\n\n1\\. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), or Pancreatic Cancer (PANC), that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n\nPart 1: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n\nPart 2 : Key Inclusion Criteria\n\n1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PANC), Mesothelioma, or Ovarian Cancer (OVAC) that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n2. Participants are germline HLA-A\\*02 heterozygous confirmed by HLA typing.\n3. Primary tumor tissue showing LOH of HLA-A\\*02 by NGS testing.\n4. Eastern Cooperative Oncology Group (ECOG) 0 or 1 performance status.\n\nPart 2: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n4. Participants who have received any cancer therapy on any investigational therapy for any indication, including but not limited to chemotherapy, small molecules, monoclonal antibodies, or radiotherapy (with bone marrow impact) within 2 weeks of planned apheresis or 3 half-lives, whichever is shorter.\n5. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment necessitating specific treatment, or any major episode of infection requiring treatment with Intravenous (IV) antimicrobials (e.g., IV antibiotics) or hospitalization (relating to completion of antibiotic course).\n6. Has known active central nervous system metastases. Subjects with previously treated brain metastases may participate upon medical monitor agreement.\n7. In the Investigator's judgement, any other condition or reason the subject would not complete the required study visits and procedures, and follow up visits, or comply with the study requirements for participation.",{"count":189,"type":21},200,"Objective:\n\nTo collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment.\n\nDesign:\n\nThis is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.",[192,193,194,195,109,105,196,197,198,199,200,201,202,203,204,27,205],"Solid Tumor, Adult","Colorectal Cancer","Non Small Cell Lung Cancer","Pancreatic Cancer","Pancreas Cancer","Mesothelioma","Ovarian Cancer","Ovarian Neoplasms","Ovarian Carcinoma","Mesothelioma, Malignant","Mesothelioma; Lung","Cancer","Triple Negative Breast Cancer (TNBC)","Head and Neck Squamous Cell Carcinoma HNSCC",[207,208,209,210,211],"CAR T Cell Therapy","Next Generation Sequencing","Leukapheresis","Apheresis","Immunotherapy","2026-05-29",{"date":214,"type":37},"2026-06-02",{"date":216,"type":37},"2021-10-29",{"date":218,"type":21},"2029-04",{"name":220,"class":118},"A2 Biotherapeutics Inc.",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":45},"100635632","pilot-study-of-bone-mineral-density-changes-during-anti-pd-1-immunotherapy-100635632","NCT07555210","Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy","Pilot Study Assessment of Bone Mineral Density Changes During Treatment With Anti-PD-1 Immunotherapy Agents","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Patients planning to start or within the first four weeks of treatment with anti-PD-1 immune checkpoint inhibitor therapy either alone or in combination with chemotherapy for curative intent for a known cancer diagnosis (use of immunotherapy must be FDA-approved and not experimental).\n3. Life expectancy of at least 12 months per the discretion of the treating physician.\n\nExclusion Criteria:\n\n1. Patients ineligible for anti-PD-1 therapy.\n2. Patients with metastatic disease.\n3. Patients planning treatment with dual immune checkpoint inhibitor therapy.\n4. Bony fractures in the pelvis, bilateral hips\u002Ffemurs, thoracic spine, or lumbar spine.\n5. Known osteoporosis or osteopenia.\n6. Planned or previous treatment with denosumab, zoledronic acid, or other bisphosphonate therapy in the last six months.\n7. Parathyroid gland disorders, rheumatoid arthritis (unless well-controlled off active biologic therapy without chronic steroid use), CKD stage IV\u002FV, or ESRD.\n8. Inability to comply with study procedures.\n9. Inability to lie flat for 20-25 minutes during an imaging session.\n10. Pregnant or breastfeeding patients.\n11. Medical or psychiatric co-morbidities that, in the opinion of the treating physician, would prevent the patient from successfully participating in the study.",{"count":229,"type":21},25,[24],"Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells. However, these agents, now approved for over 15 types of cancers and for both early-stage and metastatic disease, are capable of causing inflammation in any organ system of the body that can lead to organ damage, dysfunction, and even death in rare cases. Some patients may suffer acute and treatable complications like joint pain, but some may have irreversible complications like hypothyroidism that requires daily, life-long medication. It is therefore important to fully understand the different types of damage ICIs can cause to better monitor patients receiving ICI therapy.\n\nA rising concern from recent reports in the literature is that ICIs may weaken bone and increase the risk of fractures. In this study, the investigators aim to characterize how ICIs impact the bone by examining several factors in patients undergoing curative-intent ICI treatment either alone or in combination with chemotherapy: bone mineral density, bone volume, and markers of bone turnover in the blood. The study will use two imaging techniques to assess bone mineral density and volume. DXA (dual X-ray absorptiometry) imaging uses low-dose X-rays to measure how dense (or strong) bones are and is often used to diagnose or assess the risk of osteoporosis. High-resolution peripheral quantitative computed tomography (HRpQCT) is a 3D imaging technology that can quantify bone structure and volume and offers high resolution that can be used to assess bone in smaller bones of the peripheral skeleton.\n\nThe investigators hypothesize that ICI treatment will weaken bones and increase the risk of fractures. As ICI therapy is relatively new, a rising number of patients may be at risk of fractures or have low bone density that is not being monitored because there are no guidelines in place notifying physicians of this potential risk to patients. This is study will provide important preliminary data that will be the basis for larger studies in the future aiming to better monitor and potentially treat bone weakening in patients treated with ICIs to reduce the pain, inconvenience, and complications from fragility fractures.",[233,27,234,235,236,237,238,239],"Breast Cancer (Triple Negative Breast Cancer (TNBC))","Melanoma (Skin Cancer)","Non-Small Cell Lung Cancer","MSI-H\u002FdMMR Rectal Cancer","Squamous Cell Carcinoma Mouth","Invasive Mammary Carcinoma","Classic Hodgkin Lymphoma","2026-05-04",{"date":242,"type":37},"2026-05-06",{"date":244,"type":37},"2025-08-25",{"date":246,"type":21},"2028-07-01",{"name":248,"class":44},"Jessica Mezzanotte Sharpe",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":257,"enrollmentInfo":258,"targetDuration":260,"studyType":131,"phases":4,"briefSummary":261,"conditions":262,"keywords":268,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":277,"leadSponsor":279,"locationsCount":45},"100601955","validation-of-rcc-predicting-model-with-emulated-target-trial-100601955","NCT07117227","Validation of RCC Predicting Model With Emulated-target Trial","Emulated-target Trial for Guiding Stratified Treatment for Renal Cell Carcinoma With Venous Tumor Thrombus","RCCETT","Inclusion Criteria:\n\n* Adults ≥18 years of age;\n* Diagnosis of primary renal cell carcinoma before and during the surgery;\n* Received radical nephrectomy\u002Fnephron-sparing surgery.\n\nExclusion Criteria:\n\n* Subjects with severely missing clinical information;\n* History of other malignant tumors.\n* Recurrence observed before first postoperative follow-up.\n* Discontinue the adjuvant treatment within in the first two course because of severe adverse react.","80 Years",{"count":259,"type":21},4700,"2 Years","This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high\u002Fmedium\u002Flow risk) improves survival outcomes .",[27,141,263,264,265,266,267],"Tumor Thrombus","Prognosis","Prognostic Cancer Model","Real World Study","Observational Study",[269,270,271,272],"renal cell carcinoma","tumor thrombus","prognostic model","emulated-target trial","2026-04-08",{"date":275,"type":37},"2026-04-14",{"date":39,"type":37},{"date":278,"type":21},"2027-08-01",{"name":280,"class":44},"Peking University Third Hospital",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":289,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":179},"100610982","patient-partnered-research-in-investigating-fear-of-cancer-recurrence-in-kidney-cancer-100610982","NCT07234656","Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer","Patient-partnered Research: a Key to Investigating Fear of Cancer Recurrence in Patients With Surgically Treated Kidney Cancer (PP-RECURK)","PP-RECURK","Inclusion Criteria:\n\nPhase 1:\n\n* Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner\u002Fspouse\n* Partner\u002Fspouse to patients who fullfil the inclusion criteria\n* Patients have undergone surgery due to localized RCC (T1-T2-T3 tumor)\n* Time since surgery: 0-120 months\n* Danish speaking patients and partners\u002Fspouses. Must be able to speak, write and read Danish\n* Patients\u002Fpartners\u002Fspouses able to and willing to attend online project meetings or in person at Gødstrup Hospital.\n\nPhase 2:\n\n* Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner\u002Fspouse\n* Partner\u002Fspouse to patients who fullfill the inclusion criteria\n* Patients who have undergone surgery due to localized RCC (T1-T2-T3 tumor)\n* Danish speaking patients and partners\u002Fspouses. Must be able to speak, write and read Danish\n* Able to receive digital communication from the hospital\n* Informed consent must be signed before answering Fear of Cancer Recurrence questions\n\nExclusion Criteria:\n\nBoth phases, both patients and partners\u002Fspouses:\n\n* Diagnosed with cognitive impairment\n* Untreated psychiatric disorders due to non-compliance\n\nPhase 2:\n\n• Patients and partners\u002Fspouses who were panelists in phase 1",true,{"count":291,"type":21},105,"The goal of this observational study is to gather real-world information about Fear of Cancer Recurrence (FCR) following surgery in patients with renal cell carcinoma (RCC) and their partners\u002Fspouses by 1) establishing a panel consisting of patients with or without partners\u002Fspouses to facilitate patient-partnered research. Furthermore, 2) Through discussions among panel members and researchers identification of the most pertinent topics related to FCR, as well as the optimal timing and methods for collecting that information in the follow-up care after surgery. Finally, to conduct a feasibility and pilot study to investigate the feasibility of the recommendations developed in 1) + 2) and assess FCR in patients with RCC following surgery and their partners\u002Fspouses.\n\nIn phase 1 participants (panel members) will be asked to collaborate with researchers in the development of recommendations for FCR questions, mode of administration and timing in the follow-up care after surgically treated kidney cancer.\n\nIn phase 2 participants (patients and partners) in follow-up care after surgically treated kidney cancer are asked to answer questions about FCR at specific timepoints defined by panel members and researchers in phase 1.",[294,27],"Fear of Cancer Recurrence",[294,296,297],"Patient involvement in research","Kidney cancer","2026-03-31",{"date":300,"type":37},"2026-04-01",{"date":302,"type":37},"2025-09-30",{"date":304,"type":21},"2028-02",{"name":306,"class":44},"Brigitta Rasmussen Villumsen",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":317,"briefSummary":319,"conditions":320,"keywords":324,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":345},"100608132","phase-3-phase-3-study-to-assess-safety-and-efficacy-of-177lu-tlx250-in-advanced-relapsed-or-recurrent-ccrcc-100608132","NCT07197580","Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (Lutetium (177Lu) Girentuximab Tetraxetan) With the Investigator's Choice of a Single Agent Therapy in Participants With Carbonic Anhydrase 9 (CAIX) Expressing, Advanced Relapsed or Recurrent Clear Cell Renal Cell Carcinoma (ccRCC)","LUTEON","Inclusion Criteria:\n\n* be aged ≥ 18 years.\n* have provided written informed consent, dated and signed by the participant prior to any study-specific procedure;\n* have relapsed or recurrent, locally advanced, or metastatic RCC with histologically or cytologically confirmed diagnosis of RCC with clear cell component per American Joint Committee on Cancer Staging Manual (Edge SB et al., 2017), with or without sarcomatoid features;\n* have received at least 2 and no more than 3 prior lines of systemic therapies for locally advanced or metastatic ccRCC including a PD-1\u002FPD-L1 inhibitor (at least 2 administrations) and a VEGF\u002FVEGFR-targeting agent (including TKI or mAb) in sequence or in combination;\n* have had radiographic disease progression occurring during or after the most recent line of therapy or intolerance to most recent line of therapy;\n* have at least one measurable lesion according to RECIST, version 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions;\n* be CAIX-positive at Screening defined as having at least 1 lesion with a tumor-lesion CAIX ratio of the maximum standardized uptake value (SUVmax) to liver mean standardized uptake value SUVmean) ≥ 1.5 as determined by BICR of 89Zr-TLX250 PET outcomes;\n* have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1;\n* have recovered from the AEs related to prior lines of therapy or returned to baseline with the exception of Grade 2 neurotoxicity. Ongoing, controlled AEs, such as hypothyroidism or hypertension, are permitted;\n* have adequate organ function, defined as:\n* Bone Marrow:\n\n  * leukocytes ≥ 3,000\u002FµL;\n  * absolute neutrophil count ≥ 1500\u002FµL (administration of granulocyte colony stimulating factor is not allowed within 4 weeks prior to the first administration of 177Lu-TLX250;\n  * platelets ≥ 100,000\u002FµL (platelet transfusion is not allowed within 4 weeks prior to the first administration of 177Lu-TLX250); and\n  * hemoglobin ≥ 9g\u002FdL (red blood cell transfusion is not allowed within 2 weeks prior to the first administration of 177Lu-TLX250).\n* Liver Function:\n\n  * total bilirubin ≤ 1.5 × the upper limit of normal (ULN). For patients with known Gilbert's Syndrome ≤ 3 × ULN is permitted; and\n  * alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN or ≤ 5.0 × ULN for participants with liver metastases.\n* Renal Function:\n\n  * creatinine clearance ≥ 40 mL\u002Fmin as measured by Cockroft-Gault formula or directly calculated by 24h urine;\n  * have negative pregnancy test for women of childbearing potential (serum); and\n\nExclusion Criteria:\n\n* have any of the following:\n\n  * visceral metastatic lesions that are ≥ 1 cm that have a CAIX TLR \\\u003C 1;\n  * lytic bone metastatic lesions with a soft tissue component of at least 1 cm with a TLR \\\u003C 1; and\u002For\n  * at least one metastatic lymph node lesion with short axis ≥ 2.5 cm with a TLR \\\u003C1;\n* received prior 177Lu-TLX250 therapy, any other radioligand therapy, or any prior CAIX-targeting therapy;\n* have any known hypersensitivity to compounds of similar chemical or biologic composition to girentuximab, DFO or DOTA linker, zirconium or lutetium, and\u002For any excipient in the study drug or radiographic contrast-agents;\n* has received G-CSF or erythropoietin within 4 weeks prior to laboratory evaluations at Screening;\n* be currently receiving or have received:\n\n  * any radionuclide within 10 half-lives of the radionuclide prior to 89Zr-TLX250 administration;\n  * any type of systemic anticancer therapy within 2 weeks before the first administration of 177Lu-TLX250;\n  * prior radiotherapy within 2 weeks prior to the first administration of 177Lu-TLX250 (must have recovered from all radiation-related toxicities and not currently require steroid treatment); and\u002For\n  * prior palliative radiation (≤2 weeks of radiotherapy) within 1-week of the first administration of 177Lu-TLX250 for non-central nervous system disease; NOTE: If the investigator feels that the patient is continuing to receive some clinical benefit from standard-of-care (SOC) therapy, the patient may continue SOC therapy up until 2 weeks prior to dosing with 177Lu-TLX250.\n* have known brain metastases, unless these have been treated and stabilized for at least 4 weeks prior to the first administration of 177Lu-TLX250; Note: Participants with a history of brain metastases must have either a head CT with contrast-or brain MRI performed at Screening to document stable disease prior to the first administration of 177LuTLX250.\n* Have experienced any major trauma including major surgery (such as abdominal\u002F cardiac\u002Fthoracic surgery) within 3 weeks of administration of the first administration of 177LuTLX250;\n* be pregnant or intend to become pregnant, breastfeed, or conceive a child during the study period and for at least 42 days after last administration of 89Zr-TLX250 or 6 months after last administration of 177Lu-TLX250, depending on which study drug is administered last to the respective participant;\n* Note: Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies (see Appendix 10.4).\n* be planning to breastfeed during the study period and for 28 days after last administration of 89ZrTLX250 or 75 days after last administration of 177Lu-TLX250, depending on which study drug is administered last to the respective participant;\n* have active and uncontrolled infections requiring systemic therapy or other severe concurrent disease, which, in the opinion of the investigator, would place the participant at undue risk or interfere with the study;\n* have a history of concurrent malignancy with a life expectancy of ≤ 2 years or requirement of systemic anti-cancer therapy or requirement of local therapy that would confound study results; however; participants with the following malignancies can be enrolled into the study:\n\n  * basal cell or squamous cell carcinoma of the skin;\n  * carcinoma in situ of the cervix, breast or bladder; and\u002For\n  * incidental histologic finding of prostate cancer;\n* have a serious, non-healing wound, ulcer, or bone fracture;\n* be unable to stay in the scanner bed with the arms resting out of the thoracic and abdominal fields (i.e., arms alongside the body or raised arm position) for the duration of the scan;\n* have not had resolution of clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for laboratory parameters specified above, Grade 2 alopecia, and\u002For stable Grade 2 sensory neuropathy, according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0;\n* have inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis, etc.);\n* have a life expectancy shorter than 3 months;\n* have bleeding or thrombotic disorders or subjects at risk for severe hemorrhage;\n* have experienced any clinically significant bleeding, including hemoptysis or tumor bleeding within 2 weeks prior to the first administration of 177Lu-TLX250;\n* has evidence of a serious active or sub-clinical infection or angina pectoris (New York Heart Association \\[NYHA\\] Class III or IV), significantly prolonged QT interval or other serious illness(es) involving the cardiac, respiratory, central nervous system, renal, hepatic or hematological organ systems, that might impair the ability to complete this study or could interfere with determination of causality of any adverse effects experienced in this study, or which require treatment that could interact with study treatment; or\n* have any medical or other condition that in the opinion of the investigator(s) would preclude the subject's participation in a clinical study.",{"count":316,"type":21},40,[318],"PHASE3","Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator's choice of monotherapy aligned with Australian standard-of-care.",[106,27,141,321,322,323],"Renal Cell Cancer Metastatic","Renal Cell Cancer, Recurrent","Clear Cell Renal Cell Cancer (ccRCC)",[325,326,327,106,328,329,330,331,332,333,334,335,336],"Carbonic anhydrase 9","Clear Cell Renal Cell Cancer","Kidney Cancer","CA9","CA-9","CAIX","Girentuximab","CA9 target therapy","Positron-Emission Tomography","Radiation Therapy","Radiopharmaceuticals","Targeted Radiation","2026-03-26",{"date":300,"type":37},{"date":340,"type":37},"2026-03-25",{"date":342,"type":21},"2029-02-28",{"name":344,"class":118},"Telix Pharmaceuticals (Innovations) Pty Limited",5,{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":45},"100630241","association-between-galectin-3-levels-and-outcomes-in-patients-with-renal-cell-carcinoma-transitional-cell-carcinoma--non-small-cell-lung-cancer-and-hepatocellular-carcinoma-treated-with-pd-1pdl-1-inhibitors-100630241","NCT07485114","Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1\u002FPDL-1 Inhibitors","Inclusion Criteria:\n\n1. Must be able to read and understand the informed consent form (ICF) and follow protocol requirements\n2. Patients aged\\>=18 years\n3. Patients with renal cell carcinoma, Transitional cell carcinoma, non small cell lung cancer, and hepatocellular carcinoma\n4. Patients treated with PD-1\u002FPDL-1 inhibitors\n5. Patients prior to first cycle of PD-1\u002FPDL-1 inhibitors\n6. Subjects willing to continue and take part in the study for the throughout the study duration.\n\nExclusion Criteria:\n\n1. Female subject who is pregnant, lactating, or who want to get pregnant during the study period. Male subjects who want their partner to get pregnant.\n2. Female of child-bearing potential who can't agree to utilize medically acceptable and reliable means of birth control during the study and for 1 month following the last dose of the study.",{"count":86,"type":21},"1. Background and Rationale::\n\n   Galectin-3 (Gal-3) is a β-galactoside-binding protein involved in various biological processes, including cell proliferation, apoptosis, adhesion, and immune regulation. In cancer, Gal-3 promotes tumor progression by enhancing cell survival, metastasis, and angiogenesis. Additionally, Gal-3 can upregulate Programmed Death-Ligand 1 (PDL-1) expression on cancer cells, contributing to immune evasion. PDL-1, an immune checkpoint protein, binds to its receptor PD-1 on T cells, inhibiting their activity and allowing cancer cells to escape immune detection. The interaction between Gal-3 and PDL-1 creates an immunosuppressive tumor microenvironment, reducing the efficacy of PDL-1 inhibitor therapies. Gal-3 drives the inflammatory response and can worsen the inflammation based side effects of PD-1\u002FPDL-1 inhibitos. Understanding this interplay is crucial for optimizing treatments and improving patient outcomes in cancer immunotherapy.\n\n   The present study employs the FDA-approved, automated Architect system, initially used in cardiology, to ensure high accuracy and consistency in Gal-3 measurement. This method represents a significant advance over traditional manual ELISA kits, aiming to standardize and reproduce results across the patient cohort and to optimize the application of XGAL-3 apheresis based on robust data. The study results can help optimize the use of the XGAL-3 therapeutic apheresis as an adjuvant treatment to enhance the efficacy and reduce the side effects associated with PDL-1 inhibitors.\n\n   Therefore, the aim of this study is to conduct an observational clinical trial assessing the correlation between Galectin-3 Level and immunotherapy Outcomes in renal cell carcinoma, non small cell lung cancer, and hepatocellular carcinoma patients treated with PD-1\u002F PDL-1 Inhibitors\n2. Study Objectives:\n\n   * Primary objectives: To correlate Gal-3 levels with patient outcomes, including response to treatment, duration of response, survival, and side effects observed.\n   * Secondary objectives: To monitor and analyze serum Gal-3 level \\& fluctuations over the course of PD-1\u002FPDL-1 inhibitors in oncological patients.\n3. Study enrollment and withdrawal: Inclusion\u002FExclusion Criteria:\n\nInclusion Criteria:\n\n1. Must be able to read and understand the informed consent form (ICF) and follow protocol requirements\n2. Patients aged\\>=18 years\n3. Patients with renal cell carcinoma, Transitional cell carcinoma, non small cell lung cancer, and hepatocellular carcinoma\n4. Patients treated with PD-1\u002FPDL-1 inhibitors\n5. Patients prior to first cycle of PD-1\u002FPDL-1 inhibitors\n6. Subjects willing to continue and take part in the study for the throughout the study duration.\n\nExclusion Criteria :\n\n1. Female subject who is pregnant, lactating, or who want to get pregnant during the study period. Male subjects who want their partner to get pregnant.\n2. Female of child-bearing potential who can't agree to utilize medically acceptable and reliable means of birth control during the study and for 1 month following the last dose of the study.\n\n4\\. Study Design and Methodology: Study population: Oncology patients with renal cell carcinoma, non small cell lung cancer, and hepatocellular carcinoma, receiving PD-1\u002FPDL-1 inhibitors Study duration: 3 years Number of patients: 300 patients Study type: This is a prospective, observational. study evaluating the correlation between serum Gal-3 level \\& fluctuations and treatment outcome of immunotherapy based PD-1\u002FPDL-1 inhibitors in patients with renal cell carcinoma, non small cell lung cancer, and hepatocellular carcinoma General Study design: The study will enroll participants from the Tel Aviv Sourasky medical center who are diagnosed with renal cell carcinoma, non small cell lung cancer, and hepatocellular carcinoma, and treated with PD-1\u002FPDL-1 based immunotherapy Methodology\n\n1. Data Collection: clinical and laboratory data will be collected before treatment, including blood count and chemistry included liver function In addition, disease characteristics , demographic data (age, sex), treatment-related information (concomitant medications, dosages), and documentation of adverse events will be recorded each evaluation. All data will be entered into the CRF in accordance with study procedures.\n2. Gal-3 blood levels: collected of 3 ml before every immunotherapy administration per treatment\n3. Gal-3 blood levels testing method\n\n   * Gal-3 blood level withdrawn of 3 ml each visit before each treatment\n   * Samples will be frozen at -80°C microbiology lab and analyzed in pre-determined group size or periodical testing.\n   * Utilize the ARCHITECT platform for all testing, with reagents supplied by Eliaz Therapeutics Inc, ensuring consistency and reliability in test results.\n4. Statistical analysis: Upon trial completion, the possible correlation between Gal-3 levels and immunotherapy outcomes will be analyzed.",[27,194,355,356],"Hepatocellular Carcinoma","Transitional Cell Carcinoma","2026-03-16",{"date":359,"type":37},"2026-03-20",{"date":361,"type":37},"2025-12-03",{"date":363,"type":21},"2028-12-03",{"name":365,"class":366},"Daniel Keizman","OTHER_GOV",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":377,"briefSummary":378,"conditions":379,"keywords":382,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":394,"locationsCount":396},"100571912","phase-3-systemic-therapy-alone-or-with-stereotactic-body-radiotherapy-for-oligometastatic-kidney-cancer-stroker-study-100571912","NCT06726421","Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)","Systemic Therapy Combined With Radiotherapy Versus Systemic Therapy Alone for Oligometastatic Kidney CancER (STROKER): A Multicenter, Randomized Controlled Phase III Trial","STROKER","Inclusion Criteria:\n\n* Pathologically confirmed diagnosis of renal cell carcinoma of any histology\n* Age ≥ 18 years.\n* ECOG performance status of 0-2.\n* Imaging suggests the presence of distant metastases, with no more than 5 metastatic lesions according to RECIST 1.1 criteria and MDA standards.\n* The patient has received local therapy to primary site, including surgery, stereotactic radiotherapy, or ablation.\n* The patient has received no more than 2 lines of systemic therapy.\n* No significant impairment of major organ function:\n\nHemoglobin (HB) ≥ 80 g\u002FL Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL Platelets (PLT) ≥ 75 × 10⁹\u002FL Serum total bilirubin ≤ 1.5 × ULN Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN\n\nExclusion Criteria:\n\n* Presence of intracranial metastases.\n* Target lesions have previously received high-dose irradiation with .\n* Target lesions are unsuitable for radiation therapy judged by treating radiation oncologist (e.g., lesions invading the gastrointestinal tract or penetrating the bronchus).\n* Uncontrollable metastatic pleural effusion or ascites.\n* Presence of other malignancies that have not been cured.\n* History of significant psychiatric disorders that impede understanding of informed consent and compliance with the study protocol.\n* Presence of other serious illnesses that may pose significant risks or affect radiation therapy.\n* Women who are pregnant, breastfeeding, or with plans for childbearing during the study.\n* Any other reasons deemed by the investigator to make the subject unsuitable for participation in the study.",{"count":376,"type":21},252,[318],"This phase III randomized controlled trial evaluates the efficacy of stereotactic body radiation therapy (SBRT) in oligometastatic renal cell carcinoma. The study aims to determine if the addition of SBRT to standard systemic therapy prolong survival compared to the standard systemic therapy alone. In addition, the study will explore the impact of this combined modality therapy on patients' toxicity and quality of life. The researchers will compare SBRT plus standard systemic therapy to standard systemic therapy alone, which is targeted agents and immunotherapy in this case, to determine if SBRT could prolong survival.",[27,380,381],"Kidney Cancer Metastatic","Renal Cell Carcinoma Metastatic",[383,384,385,386,387],"radiotherapy","SBRT","SABR","oligometastatic","oligometastasis","2026-01-14",{"date":390,"type":37},"2026-01-15",{"date":392,"type":37},"2024-09-18",{"date":41,"type":21},{"name":395,"class":44},"Sun Yat-sen University",9,{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":4},"100619949","multi-omics-analysis-of-renal-cell-carcinoma-mechanisms-drug-sensitivity-testing-in-patient-derived-cell-based-microtumors-100619949","NCT07351266","Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors","Inclusion Criteria:\n\n* Histologically confirmed renal cell carcinoma with regional lymph node metastasis.\n* Primary tumor with a maximum diameter ≥ 7 cm.\n* Tumor exhibits a multinodular distribution pattern on cross-section (assessed via intraoperative or postoperative gross specimen).\n* Age \\> 18 years.\n* Ability to understand the study and voluntarily provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of distant metastasis (M1 stage).\n* Prior receipt of any targeted therapy or immunotherapy for renal cell carcinoma before surgery.\n* History of other active malignancies besides RCC (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).\n* Any psychiatric, neurological, or legal condition that may compromise the ability to understand the informed consent or to comply with study procedures.",{"count":404,"type":21},10,"This is a research study aiming to better understand a type of kidney cancer called Renal Cell Carcinoma (RCC). Doctors have observed that inside some larger RCC tumors, there are multiple smaller nodules. This study wants to find out if these nodules are different from each other and how they might be related.\n\nTo do this, researchers will study tumor tissue samples from 10 patients with RCC who are having surgery. From each tumor, several nodules will be analyzed using advanced laboratory techniques. These techniques will create very detailed maps of the genes and cells within each nodule. At the same time, tiny 3D tumor models (called microtumors) will be grown from these samples in the lab to test how they respond to different cancer drugs.\n\nThe main goal is to combine these two types of information to see how the differences in genes and cells between nodules might explain why some tumors stop responding to treatment (become resistant). We hope this study will lead to a deeper understanding of how RCC grows and spreads, and help find new ways to diagnose and treat it in the future.",[27],[408,409,410,411,412,413,414,415,416],"Multi-omics","Single-Cell Sequencing","Spatial Transcriptomics","Whole Exome Sequencing","Microtumors","Patient-Derived Cells","Drug Sensitivity Testing","Tumor Heterogeneity","Intratumoral Nodules","2026-01-12",{"date":419,"type":37},"2026-01-20",{"date":421,"type":21},"2026-01-25",{"date":423,"type":21},"2030-01-25",{"name":425,"class":44},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":289,"sex":17,"minAge":434,"maxAge":435,"enrollmentInfo":436,"targetDuration":4,"studyType":22,"phases":438,"briefSummary":439,"conditions":440,"keywords":444,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":45},"100606103","targeted-abdominal-ct-in-conjunction-with-lung-cancer-screening-100606103","NCT07171190","Targeted Abdominal CT in Conjunction With Lung Cancer Screening","Targeted Abdominal CT in Conjunction With Lung Cancer Screening - a Pilot Study (TACTICAL1): a Randomised Controlled Pilot Study of Adding Abdominal Non-contrast CT to Lung Cancer Screening CT Thorax Amongst High Lung Cancer Risk Ever-smokers Aged 55-70.","TACTICAL1","1. For the individual level randomisation to invitation control or invitation intervention\n\n   Inclusion criteria: To be randomised at the individual level to receive an invitation letter for LCS (standard of care; invitation control) versus invitation letter for LCS with potential for an additional abdominal scan (invitation intervention):\n   * Be eligible to be invited to the first round of a West Yorkshire and Harrogate LCS or a Humber and North Yorkshire Cancer Alliance LCS (i.e. have been identified as a smoker or ex-smoker and registered as living within the relevant LCS catchment area).\n   * Be registered with a GP in England.\n   * Be aged 55-70 years 364 days old at the date of invitation.\n\n   Exclusion criteria\n\n   • None\n2. Eligibility criteria for the cluster level randomisation to scan intervention or scan control\n\n   Inclusion criteria a): To be eligible for the cluster level randomisation the participant must:\n   * Have been individually randomised to the invitation intervention arm\n   * Have booked in for a LCS assessment\n\n   Inclusion criteria b): To receive the CT Thorax plus ANCCT, the participant must:\n   * Have been randomised to the scan intervention cluster\n   * Be invited to attend for a LDCT Thorax based upon scores on either PLCOM2012 or Liverpool Lung Project (LLP) risk prediction models (PLCOM2012 risk of ≥1.51% over six years or LLPver2 five-year risk of ≥2.5%)14 during the LCS assessment.\n   * Have attended the lung scan appointment\n   * Have given electronic or written informed consent to participate\n\n   Exclusion criteria\n\n   Existing LCS exclusion criteria:\n   * Participant does not have capacity to give consent (standard criteria for assessing capacity apply).\n   * Weight or physical size exceeds restrictions for scanner (\\>200kg).\n   * Participant unable to lie flat.\n   * Poor physical fitness such that treatment with curative intent would be contra-indicated.\n   * Participants who have had a full CT Thorax that meets the image reconstruction parameters of the programme in the last 12 months are not excluded from the lung screening programme, but would have their CT Thorax appointment deferred until 12 months have elapsed since that last scan, provided they still meet all inclusion criteria and have no exclusion criteria - if the deferred appointment is within the timeframe for TACTICAL1, they remain eligible but if deferred appointment is outside the timeframe for TACTICAL1 they would not be eligible.\n\n   Additional TACTICAL1 exclusion criteria:\n\n   • Had an abdominal CT in the previous 12 months or has one booked within the next 3 months.\n   * For HNY, this is checked before the LCS assessment. Therefore, participants will be excluded before the LCS assessment.\n   * For WYH, this is only checked after the LCS assessment. Therefore, anyone having had an abdominal CT in the previous 12 months or with one booked within the next 3 months will be excluded at this point (see 8.6).\n3. Eligibility criteria for the process evaluation Health care professionals: Healthcare professionals involved in the delivery of LCS in any of the study areas who agree to take part.\n\nParticipants: People individually randomised to the invitation intervention arm who attend the LCS assessment or the scanning unit within the study period and who agree to be interviewed.","55 Years","70 Years",{"count":437,"type":21},6272,[24],"Early detection through screening can improve cancer survival by identifying it when it's most treatable. The NHS now offers Lung Cancer Screening (LCS) assessments to people aged 55-74 who have ever smoked. Those at higher risk of lung cancer are offered a lung scan.\n\nThis group also has a high risk of developing abdominal cancers, such as kidney cancer. A recent study explored whether it would be feasible to extend the lung scan to include the abdomen. Results showed most participants supported this addition, and the number of serious findings was similar to those detected in UK breast or bowel cancer screening programmes.\n\nHowever, the abdominal scan was only offered on the day of the lung scan, giving little time for people to consider their decision. The process also added too much time to be practical for widespread implementation.\n\nThis new study will:\n\n* Test whether mentioning the possible abdominal scan in the initial LCS invitation affects participation in LCS assessments.\n* Test new processes to assess if the abdominal scan can be added to the lung scan with minimal extra time.\n* Check if participants can be split between the lung scan only group and lung and abdominal scan group using an approach called 'cluster randomisation'. This will be important in case a bigger trial is needed.\n* See whether the additional processes are acceptable\n\nPeople aged 55-70 who are invited to the lung cancer screening will be eligible to take part in this study. Only those who are found to be at a high risk of lung cancer after their assessment, and therefore offered a lung scan, will be offered the abdominal scan, provided they have not had an abdominal scan in the previous 12 months or one booked in the next 3 months.\n\nThis study will take place in two existing lung cancer screening locations in Yorkshire.",[27,441,442,443],"Kidney Cancers","AAA - Abdominal Aortic Aneurysm","Renal Stones",[445,446,297,447,448,449,450],"Screening","NHS Lung Cancer Screening","Abdominal cancer","Lung cancer","Abdominal Aortic Aneurysms (AAA)","Abdominal screening","2025-12-12",{"date":453,"type":37},"2025-12-19",{"date":455,"type":37},"2025-11-11",{"date":457,"type":21},"2027-10",{"name":459,"class":44},"University of Cambridge",{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":45},"100602077","application-of-radiomics-based-ai-models-in-predicting-clinical-outcome-of-patients-with-renal-cell-carcinoma-after-surgical-treatment-100602077","NCT07118813","Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment","Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment (AI-Kidney-Prognosis)","Inclusion Criteria:\n\n1. Patients were treated for renal cell carcinoma in Wuhan Union Hospital from August 2025 to August 2026;\n2. Aged \\> 18 years old;\n3. At least one abdominal CT scan before treatment;\n4. Tissue biopsy pathological examination confirmed the diagnosis of renal cell carcinoma.\n\nExclusion Criteria:\n\n1. Poor image quality;\n2. Incomplete clinical data or loss of follow-up;\n3. Presence of another primary malignancy other than renal cell carcinoma;\n4. Unclear pathological diagnosis.",{"count":468,"type":21},400,"This is a prospective observational cohort study (AI-Kidney-Prognosis), aiming to non-invasively predict the clinical outcomes in renal cell carcinoma patients after surgical treatment using radiomics-based AI models, thereby assisting clinical decision-making and personalized follow-up strategies.",[27],"2025-08-05",{"date":473,"type":37},"2025-08-12",{"date":475,"type":21},"2025-08",{"date":477,"type":21},"2026-08",{"name":479,"class":44},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":22,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":45},"100597750","phase-1-study-of-111in-xyimsr-01-spectct-in-patients-with-metastatic-clear-cell-renal-cell-100597750","NCT07062549","Study of 111In-XYIMSR-01 SPECT\u002FCT in Patients With Metastatic Clear Cell Renal Cell","First-in-Human Study of 111In-XYIMSR-01 SPECT\u002FCT in Patients With Metastatic Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n* Males or female sex\n* ≥18 years of age\n* Willingness to provide signed informed consent and comply with all protocol requirements\n* Histological confirmation of RCC with a clear cell component\n* 2-10 sites of disease measuring ≥1.5 cm on contrast-enhanced CT and\u002For MRI imaging of the chest, abdomen and pelvis performed ≤60 days prior to the date of study enrollment\n* Screening clinical laboratory values as specified below:\n\n  * Serum bilirubin ≤ 1.5 times the upper limit of normal; for patients with known Gilbert's syndrome, ≤ 3 × ULN is permitted\n  * ALT ≤ 3 times the upper limits of normal\n  * AST ≤ 3 times the upper limits of normal\n  * Creatinine clearance ≥50 mL\u002Fmin based on Cockcroft-Gault formula\n  * Absolute neutrophil count ≥ 1,500 \u002Fmm3\n  * Platelets ≥100,000\u002F mm3\n  * Hemoglobin ≥ 9.0 g\u002FdL\n  * White blood cell count ≥ 2,000\u002F mm3\n\nExclusion Criteria:\n\n* Systemic therapy for the treatment of ccRCC within 12 months of study enrollment.\n* Subjects administered any radioisotope within five physical half-lives prior to study drug injection.\n* Subjects with any medical condition or other circumstances that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.\n* Women of child-bearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin) within 24 hours prior to the imaging day.\n* Women must not be breastfeeding.",{"count":488,"type":21},6,[88],"This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan",[27],"2025-07-17",{"date":494,"type":37},"2025-07-23",{"date":496,"type":37},"2022-01-26",{"date":498,"type":21},"2029-07",{"name":500,"class":44},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":22,"phases":509,"briefSummary":510,"conditions":511,"keywords":512,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":4},"100589881","virtual-renality-assessing-the-impact-of-virtual-reality-on-preoperative-planning-in-renal-cancer-surgery-100589881","NCT06960174","Virtual Renality: Assessing the Impact of Virtual Reality on Preoperative Planning in Renal Cancer Surgery","Inclusion Criteria:\n\n* 18+\n* Suspected RCC and candidate for (partial) nephrectomy\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patients who are not approved to undergo surgery (due to comorbidities or their overall health condition)\n* Patients who are unable to give informed consent",{"count":508,"type":21},70,[24],"Rationale:\n\nPreoperative planning for both partial and radical nephrectomies using conventional CT imaging can be challenging due to complex renal anatomy and vascularization. 3D models in virtual reality (VR) may enhance anatomical understanding and improve preoperative planning. This study aims to prospectively evaluate the clinical impact of the use of 3D models in VR in the preoperative planning of partial and radical nephrectomies.\n\nObjective:\n\nThe primary objective is to assess the impact of VR on preoperative planning and thereby on the agreement between the preoperative plan and the performed surgery in renal surgery (both partial and radical nephrectomies). The secondary objectives focus on the urologist's understanding of the anatomy and how the intraoperative and postoperative outcomes are influenced by the use of VR in the preoperative planning.\n\nStudy design:\n\nThe Virtual Renality study is a single-center randomized clinical trial conducted at the St. Antonius Hospital in Nieuwegein.\n\nStudy population:\n\nThe study population will consist of adult patients (18+) with a suspected RCC who are indicated for (partial) nephrectomy at St. Antonius Hospital Nieuwegein.\n\nIntervention:\n\nFor the intervention group, the urologist will review a 3D virtual model of the renal anatomy in addition to the original CT scan during preoperative planning. For the control group, only the CT scan will be used for preoperative planning, according to the current standard of care.\n\nMain study parameters\u002Fendpoints:\n\nThe primary study endpoint is the surgical concordance score, which describes the concordance between the actual performed surgery and the preoperatively determined surgical plan.\n\nNature and extent of the burden and risks associated with participation, benefit, and group relatedness:\n\nParticipation in this study will not require any additional physical examinations, blood samples, hospital visits, or questionnaires beyond standard clinical care. The only difference for participants in the intervention group is that a 3D model will be created from the existing CT scan and reviewed in VR during preoperative planning by the urologist.",[27],[513,514,515,516,517,518],"Renal Cell Carcinoma","Partial nephrectomy","Radical nephrectomy","Preoperative planning","3D virtual model","Virtual Reality","2025-04-28",{"date":521,"type":37},"2025-05-07",{"date":523,"type":21},"2025-06-02",{"date":525,"type":21},"2026-01-31",{"name":527,"class":44},"St. Antonius Hospital"]